HMGB1 and COVID-19: Given the role of the TLR4/HMGB1 axis in the progression of pulmonary inflammation—including with cytokine storms occurring with COVID-19—our results indicate that leytragin is a promising therapeutic agent for the prevention of cytokine storm with COVID-19.